327
Views
3
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Real-World Experience on the Use of Mepolizumab from the Severe Asthma Registry of the German Asthma Net (MepoGAN-Study)

, ORCID Icon, ORCID Icon, , , , , ORCID Icon & show all
Pages 541-552 | Received 31 Dec 2022, Accepted 01 May 2023, Published online: 11 May 2023

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Corrado Pelaia, Antonio Giacalone, Gianluca Ippolito, Daniela Pastore, Angelantonio Maglio, Giovanna Lucia Piazzetta, Nadia Lobello, Nicola Lombardo, Alessandro Vatrella & Girolamo Pelaia. (2024) Difficult-To-Treat and Severe Asthma: Can Real-World Studies On Effectiveness of Biological Treatments Change the Lives of Patients?. Pragmatic and Observational Research 15, pages 45-51.
Read now

Articles from other publishers (2)

Ibrahim M Dighriri, Anas I Alnughaythir, Amna A Albesisi, ‏Danya I Alhuwaimel, Alanoud S Alotaibi, Laila A Alghowaidi, Fatimah H Almalki, Jasmine N Al-Bukhari, Tahani R Alshammari, Fahad H Alwathnani, Abdulmohsen A Alghamdi, Ali A Alghamdi, Safar D Alshehri, Nora Y Mahnashi & Hassan A Abu Jamilah. (2023) Efficacy and Safety of Mepolizumab in the Management of Severe Eosinophilic Asthma: A Systematic Review. Cureus.
Crossref
Laura Bergantini, Tommaso Pianigiani, Miriana d’Alessandro, Sara Gangi, Behar Cekorja, Elena Bargagli & Paolo Cameli. (2023) The effect of anti-IL5 monoclonal antibodies on regulatory and effector T cells in severe eosinophilic asthma. Biomedicine & Pharmacotherapy 166, pages 115385.
Crossref